Regents of the University of California’s Intellia Therapeutics NTLA Stock Holding History

Regents of the University of California’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-117,315	Closed	-$2.63M	–	5
2024 Q2	$2.63M	Hold	117,315	–	–	1.44%	3
2024 Q1	$3.23M	Hold	117,315	–	–	0.94%	5
2023 Q4	$3.58M	Buy	117,315 +5,875	+5%	+$169K	0.45%	6
2023 Q3	$3.52M	Hold	111,440	–	–	0.45%	7
2023 Q2	$4.54M	Hold	111,440	–	–	0.57%	6
2023 Q1	$4.15M	Hold	111,440	–	–	0.77%	4
2022 Q4	$3.89M	Hold	111,440	–	–	0.74%	4
2022 Q3	$6.24M	Hold	111,440	–	–	1.26%	5
2022 Q2	$5.77M	Hold	111,440	–	–	1.16%	7
2022 Q1	$8.1M	Hold	111,440	–	–	1.22%	8
2021 Q4	$13.2M	Hold	111,440	–	–	1.85%	7
2021 Q3	$14.9M	Hold	111,440	–	–	1.76%	8
2021 Q2	$18M	Hold	111,440	–	–	2.3%	7
2021 Q1	$8.94M	Hold	111,440	–	–	1.17%	8
2020 Q4	$6.06M	Hold	111,440	–	–	0.88%	7
2020 Q3	$2.21M	Hold	111,440	–	–	0.31%	9
2020 Q2	$2.34M	Hold	111,440	–	–	0.33%	10
2020 Q1	$1.36M	Hold	111,440	–	–	0.2%	11
2019 Q4	$1.64M	Hold	111,440	–	–	0.86%	13
2019 Q3	$1.49M	Hold	111,440	–	–	2.85%	9
2019 Q2	$1.82M	Sell	111,440 -412,983	-79%	-$6.49M	5.15%	6
2019 Q1	$11.1M	Hold	524,423	–	–	26.04%	1
2018 Q4	$7.16M	Hold	524,423	–	–	17.31%	1
2018 Q3	$15M	Hold	524,423	–	–	29.21%	1
2018 Q2	$14.3M	Hold	524,423	–	–	37.54%	1
2018 Q1	$11.1M	Hold	524,423	–	–	20.27%	2
2017 Q4	$10.1M	Buy	+524,423	New	+$12.1M	15.19%	2

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Regents of the University of California's NTLA Position: Q3 2024 in Review

Regents of the University of California sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 117,315 shares — an estimated $2.63M sold.

Regents of the University of California first reported a position in NTLA in Q4 2017 and held it in 27 quarters. The position peaked at $18M in Q2 2021. 284 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

Regents of the University of California reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
Regents of the University of California sold 117,315 Intellia Therapeutics shares in Q3 2024, an estimated $2.63M.
Regents of the University of California first reported a position in Intellia Therapeutics in Q4 2017 and held it in 27 quarters.
Regents of the University of California's Intellia Therapeutics position peaked at $18M in Q2 2021.
284 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Regents of the University of California's 13F filing for Q3 2024, filed 12 Nov 2024.